Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Sanofi SA News

    85,73 € -0,82% -0,71 €
    11:15:24 Uhr Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 920657
    ISIN: FR0000120578
    US-Symbol: SNYNF
    Typ: Aktie
    Werbung

    Attraktive Knock-Outs auf Sanofi SA

    Typ Hebel Bid / Ask WKN Typ Hebel Bid / Ask WKN
    Call
    		5,2 1,63 € / 1,64 €
    SN5673
    Put
    		4,8 1,80 € / 1,81 €
    SU0ZVW
    Call
    		10,0 0,85 € / 0,86 €
    SN567Z
    Put
    		10,7 0,81 € / 0,82 €
    SU8GL1
    Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
    Alle Knock-Outs auf Sanofi SA
    Werbung
    Weiter abwärts?
    Short Hebel 12,54
    UM2DBV

    Ad-hocs

    17.04.24 - GlobeNewswire
    Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
    New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
    22.03.24 - GlobeNewswire
    Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
    Availability of the Q1 2024 Memorandum for modelling purposes
    11.03.24 - GlobeNewswire
    Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
    New Phase 2b results for amlitelimab support potential for best-​in-class maintenance of response in atopic dermatitis
    24.02.24 - GlobeNewswire
    Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
    Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
    23.02.24 - GlobeNewswire
    Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
    Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
    23.02.24 - GlobeNewswire
    Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
    Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
    22.02.24 - GlobeNewswire
    Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
    Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
    16.02.24 - GlobeNewswire
    Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
    Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU)
    15.02.24 - GlobeNewswire
    Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
    Phase 2 data published in NEJM show potential of frexalimab as high-​efficacy therapy in relapsing MS
    05.02.24 - GlobeNewswire
    Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
    Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
    01.02.24 - GlobeNewswire
    Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
    François-​Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
    01.02.24 - GlobeNewswire
    Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
    Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
    25.01.24 - GlobeNewswire
    Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
    Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
    23.01.24 - GlobeNewswire
    Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
    Sanofi to acquire Inhibrx, Inc., adding potential best-​in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline Acquisition supports Sanofi’s portfolio growth strategy ...
    09.01.24 - GlobeNewswire
    Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
    Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee Paris, January 9, 2024 . Brian Foard, a healthcare industry veteran and ...
    21.12.23 - GlobeNewswire
    Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
    Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
    15.12.23 - GlobeNewswire
    Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
    Availability of the Q4 2023 Memorandum for modelling purposes
    15.12.23 - GlobeNewswire
    Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
    EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
    11.12.23 - GlobeNewswire
    Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
    Statement on FTC challenge to proposed license agreement with Maze Therapeutics
    11.12.23 - GlobeNewswire
    Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
    Sarclisa ® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-​eligible patients with newly diagnosed multiple myeloma versus ...

    Newssuche

    Videos

    09:30 Uhr
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »